R&D | May 25, 2026
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Subscribe To Our Newsletter & Stay Updated
